Precision BioSciences, Inc. (DTIL)
9.87
+1.75
(+21.55%)
USD |
NASDAQ |
Nov 05, 16:00
9.80
-0.07
(-0.71%)
After-Hours: 07:48
Precision BioSciences Enterprise Value : 221.18M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 221.18M |
| November 04, 2026 | 172.37M |
| November 03, 2026 | 140.29M |
| November 02, 2026 | 139.73M |
| October 30, 2026 | 142.80M |
| October 29, 2026 | 153.40M |
| October 28, 2026 | 154.24M |
| October 27, 2026 | 135.27M |
| October 26, 2026 | 124.67M |
| October 23, 2026 | 131.08M |
| October 22, 2026 | 134.99M |
| October 21, 2026 | 133.04M |
| October 20, 2026 | 128.85M |
| October 19, 2026 | 118.53M |
| October 16, 2026 | 106.82M |
| October 15, 2026 | 117.97M |
| October 14, 2026 | 114.07M |
| October 13, 2026 | 116.02M |
| October 12, 2026 | 128.02M |
| October 09, 2026 | 133.32M |
| October 08, 2026 | 125.23M |
| October 07, 2026 | 120.21M |
| October 06, 2026 | 118.81M |
| October 05, 2026 | 121.88M |
| October 02, 2026 | 121.88M |
| Date | Value |
|---|---|
| October 01, 2026 | 122.44M |
| September 30, 2026 | 120.48M |
| September 29, 2026 | 103.91M |
| September 28, 2026 | 105.50M |
| September 25, 2026 | 104.97M |
| September 24, 2026 | 107.88M |
| September 23, 2026 | 108.67M |
| September 22, 2026 | 130.61M |
| September 21, 2026 | 112.37M |
| September 18, 2026 | 116.86M |
| September 17, 2026 | 116.86M |
| September 16, 2026 | 115.81M |
| September 15, 2026 | 115.28M |
| September 14, 2026 | 121.89M |
| September 11, 2026 | 130.08M |
| September 10, 2026 | 131.93M |
| September 09, 2026 | 132.20M |
| September 08, 2026 | 136.16M |
| September 04, 2026 | 138.01M |
| September 03, 2026 | 135.37M |
| September 02, 2026 | 137.48M |
| September 01, 2026 | 142.50M |
| August 31, 2026 | 142.50M |
| August 28, 2026 | 146.21M |
| August 27, 2026 | 162.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 539.10M |
| Amgen, Inc. | 289.78B |
| Anika Therapeutics, Inc. | 245.53M |
| BioCryst Pharmaceuticals, Inc. | 2.407B |
| Imunon, Inc. | 5.181M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.586M |
| Total Expenses (Quarterly) | 7.586M |
| EPS Diluted (Quarterly) | -0.2765 |
| Earnings Yield | -13.01% |
| Normalized Earnings Yield | -13.87 |